• 6308 Citations
  • 33 h-Index
1991 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

  • 6308 Citations
  • 33 h-Index
  • 118 Article
  • 6 Review article
  • 5 Letter
  • 1 Comment/debate
Filter
Article
Article

A 2-es típusú Janus tirozin kináz Val617Phe aktiváló pontmutáció szerepe és kimutatásának jelentosége myeloproliferatív szindrómában

Translated title of the contribution: Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detectionAndrikovics, H., Szilvási, A., Meggyesi, N., Király, V., Halm, G., Lueff, S., Nahajevszky, S., Mikala, G., Sipos, A., Lovas, N., Csukly, Z., Mátrai, Z., Tamáska, J., Tordai, A. & Masszi, T., Feb 4 2007, In : Orvosi hetilap. 148, 5, p. 203-210 8 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)

Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza

Gézsi, A., Budde, U., Deák, I., Nagy, E., Mohl, A., Schlammadinger, Á., Boda, Z., Masszi, T., Sadler, J. E. & Bodó, I., Jun 1 2010, In : Journal of Thrombosis and Haemostasis. 8, 6, p. 1273-1280 8 p.

Research output: Contribution to journalArticle

18 Citations (Scopus)

Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients

Meggyesi, N., Kozma, A., Halm, G., Nahajevszky, S., Bátai, Á., Fekete, S., Barta, A., Ujj, G., Lueff, S., Sipos, A., Ádám, E., Bors, A., Reményi, P., Masszi, T., Tordai, A. & Andrikovics, H., Dec 1 2011, In : Acta Haematologica. 127, 1, p. 34-42 9 p.

Research output: Contribution to journalArticle

16 Citations (Scopus)

Akut szívizom-infarctusban végzett elso magyar autológ csontveloi ossejt transzplantációk során szerzett tapasztalataink

Translated title of the contribution: Experiences with the first, Hungarian autologous bone marrow cell transplantation in acute myocardial infarctionVértesljai, M., Piróth, Z., Fontos, G., Tóth, A., Simor, T., Lueff, S., Reményi, P., Réti, M., Masszi, T. & Andréka, P., Jan 8 2006, In : Orvosi hetilap. 147, 1, p. 3-6 4 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Allogeneic bone marrow transplantation for acute leukaemia - IGCI experience

Labar, B., Masszi, T., Morabito, F., Mistrik, M., Holowiecki, J., Bogdaníc, V., Nemet, D., Mrsić, M., Krieger, O. & Lutz, D., Jun 1 1996, In : Bone Marrow Transplantation. 17, 6, p. 1009-1012 4 p.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Allogeneic bone marrow transplantation for acute leukemia in adults

Masszi, T., Reményi, P., Kriván, G., Goda, V. & Réti, M., Dec 1 1998, In : Bone Marrow Transplantation. 22, SUPPL. 4, p. S77-S79

Research output: Contribution to journalArticle

1 Citation (Scopus)

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: Comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus cy as conditioning regimen-A report from the acute leukemia working party of theeuropean group for blood and marrow transplantation

Nagler, A., Rocha, V., Labopin, M., Unal, A., Ben Othman, T., Campos, A., Volin, L., Poire, X., Aljurf, M., Masszi, T., Socie, G., Sengelov, H., Michallet, M., Passweg, J., Veelken, H., Yakoub-Agha, I., Shimoni, A. & Mohty, M., Oct 1 2013, In : Journal of Clinical Oncology. 31, 28, p. 3549-3556 8 p.

Research output: Contribution to journalArticle

85 Citations (Scopus)

Allogen transzplantacio periferias haemopoeticus ossejtekkel

Translated title of the contribution: Allogeneic peripheral blood stem cell transplantationMasszi, T., Oct 2 1997, In : Lege Artis Medicinae. 7, 1-2, p. 42-45 4 p.

Research output: Contribution to journalArticle

A myeloma multiplex bortezomibalapú kezelése: Hazai tapasztalatok az elso 60 beteg adatainak tükrében

Translated title of the contribution: Single-site experience with bortezomib-based therapy of multiple myeloma: Treatment results of 60 patientsGábor, M., Árpád, B., Andrea, C., Zoltán, C., János, D., Gabriella, H., Judit, J., Balázs, K., Nóra, L., Sándor, L., Mónika, P., Péter, R., Andrea, S., Zsuzsanna, T. & Tamás, M., Jan 1 2007, In : Lege Artis Medicinae. 17, 1, p. 26-34 9 p.

Research output: Contribution to journalArticle

An Alu-mediated novel large deletion is the most frequent cause of type 3 von Willebrand disease in Hungary

Mohl, A., Marschalek, R., Masszi, T., Nagy, E., Obser, T., Oyen, F., Sallai, K., Bodó, I. & Schneppenheim, R., Sep 30 2008, In : Journal of Thrombosis and Haemostasis. 6, 10, p. 1729-1735 7 p.

Research output: Contribution to journalArticle

18 Citations (Scopus)

Analyses of donor-derived keratinocytes in hairy and nonhairy skin biopsies of female patients following allogeneic male bone marrow transplantation

Nemeth, K., Key, S., Bottlik, G., Masszi, T., Mezey, E. & Karpati, S., Jan 1 2012, In : Stem Cells and Development. 21, 1, p. 152-157 6 p.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Sureda, A., Chabannon, C., Masszi, T., Pohlreich, D., Scheid, C., Thieblemont, C., Wahlin, B. E., Sakellari, I., Russell, N., Janikova, A., Dabrowska-Iwanicka, A., Touzeau, C., Esquirol, A., Jantunen, E., van der Werf, S., Bosman, P., Boumendil, A., Liu, Q., Celanovic, M., Montoto, S. & 1 others, Dreger, P., Mar 1 2020, In : Bone Marrow Transplantation. 55, 3, p. 613-622 10 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Analysis of platelet α2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy

Béres, B. J., Tóth-Zsámboki, E., Vargová, K., László, Á., Masszi, T., Kerecsen, G., Préda, I. & Kiss, R. G., Nov 1 2008, In : Thrombosis and Haemostasis. 100, 5, p. 829-836 8 p.

Research output: Contribution to journalArticle

24 Citations (Scopus)

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Orlowski, R. Z., Gercheva, L., Williams, C., Sutherland, H., Robak, T., Masszi, T., Goranova-Marinova, V., Dimopoulos, M. A., Cavenagh, J. D., Špička, I., Maiolino, A., Suvorov, A., Bladé, J., Samoylova, O., Puchalski, T. A., Reddy, M., Bandekar, R., van de Velde, H., Xie, H. & Rossi, J. F., Jan 1 2015, In : American Journal of Hematology. 90, 1, p. 42-49 8 p.

Research output: Contribution to journalArticle

74 Citations (Scopus)

Apoptosis induction by retinoids in eosinophilic leukemia cells: Implication of retinoic acid receptor-α signaling in all-trans-retinoic acid hypersensitivity

Robert, C., Delva, L., Balitrand, N., Nahajevszky, S., Masszi, T., Chomienne, C. & Papp, B., Jun 15 2006, In : Cancer Research. 66, 12, p. 6336-6344 9 p.

Research output: Contribution to journalArticle

19 Citations (Scopus)

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Harousseau, J. L., Martinelli, G., Jedrzejczak, W. W., Brandwein, J. M., Bordessoule, D., Masszi, T., Ossenkoppele, G. J., Alexeeva, J. A., Beutel, G., Maertens, J., Vidriales, M. B., Dombret, H., Thomas, X., Burnett, A. K., Robak, T., Khuageva, N. K., Golenkov, A. K., Tothova, E., Mollgard, L., Park, Y. C. & 3 others, Bessems, A., De Porre, P. & Howes, A. J., Nov 19 2009, In : Blood. 114, 6, p. 1166-1173 8 p.

Research output: Contribution to journalArticle

100 Citations (Scopus)

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Hájek, R., Masszi, T., Petrucci, M. T., Palumbo, A., Rosiñol, L., Nagler, A., Yong, K. L., Oriol, A., Minarik, J., Pour, L., Dimopoulos, M. A., Maisnar, V., Rossi, D., Kasparu, H., Van Droogenbroeck, J., Yehuda, D. B., Hardan, I., Jenner, M., Calbecka, M., Dávid, M. & 12 others, De La Rubia, J., Drach, J., Gasztonyi, Z., Górnik, S., Leleu, X., Munder, M., Offidani, M., Zojer, N., Rajangam, K., Chang, Y. L., San-Miguel, J. F. & Ludwig, H., Jan 1 2017, In : Leukemia. 31, 1, p. 107-114 8 p.

Research output: Contribution to journalArticle

64 Citations (Scopus)

Autologus blood/marrow transplantation: Autologous stem cell transplantation for malignant lymphomas

Reményi, P., Masszi, T., Kriván, G., Goda, V. & Réti, M., Dec 1 1998, In : Bone Marrow Transplantation. 22, SUPPL. 4, p. S104-S106

Research output: Contribution to journalArticle

1 Citation (Scopus)

Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study

O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., Bhat, G., Choi, M. R., Walewski, J., Savage, K., Foss, F., Allen, L. F. & Shustov, A., Aug 10 2015, In : Journal of Clinical Oncology. 33, 23, p. 2492-2499 8 p.

Research output: Contribution to journalArticle

194 Citations (Scopus)

Bone marrow transplantation in non-malignant disorders

Kriván, G., Timár, L., Goda, V., Réti, M., Reményi, P. & Masszi, T., Dec 1 1998, In : Bone Marrow Transplantation. 22, SUPPL. 4, p. S80-S83

Research output: Contribution to journalArticle

6 Citations (Scopus)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

Ludwig, H., Greil, R., Masszi, T., Spicka, I., Shpilberg, O., Hajek, R., Dmoszynska, A., Paiva, B., Vidriales, M. B., Esteves, G., Stoppa, A. M., Robinson, D., Chaturvedi, S., Ataman, O., Enny, C., Feng, H., van de Velde, H. & Viterbo, L., Nov 2015, In : British Journal of Haematology. 171, 3, p. 344-354 11 p.

Research output: Contribution to journalArticle

18 Citations (Scopus)

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

Gambacorti-Passerini, C., Brümmendorf, T. H., Kim, D. W., Turkina, A. G., Masszi, T., Assouline, S., Durrant, S., Kantarjian, H. M., Khoury, H. J., Zaritskey, A., Shen, Z. X., Jin, J., Vellenga, E., Pasquini, R., Mathews, V., Cervantes, F., Besson, N., Turnbull, K., Leip, E., Kelly, V. & 1 others, Cortes, J. E., Jul 2014, In : American Journal of Hematology. 89, 7, p. 732-742 11 p.

Research output: Contribution to journalArticle

67 Citations (Scopus)

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial

Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., Osmanov, D., Bachanova, V., Sweetenham, J., Sureda, A., Huebner, D., Sievers, E. L., Chi, A., Larsen, E. K., Hunder, N. N. & Walewski, J., May 9 2015, In : The Lancet. 385, 9980, p. 1853-1862 10 p.

Research output: Contribution to journalArticle

354 Citations (Scopus)

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms

Mózes, R., Gángó, A., Sulák, A., Vida, L., Reiniger, L., Timár, B., Krenács, T., Alizadeh, H., Masszi, T., Gaál-Weisinger, J., Demeter, J., Csomor, J., Matolcsy, A., Kajtár, B. & Bödör, C., Apr 2019, In : Pathology. 51, 3, p. 301-307 7 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

ASPIRE Investigators, Jan 8 2015, In : New England Journal of Medicine. 372, 2, p. 142-152 11 p.

Research output: Contribution to journalArticle

676 Citations (Scopus)

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V., Schwarer, A. & 11 others, Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S. & Chng, W. J., Jan 1 2016, In : The Lancet Oncology. 17, 1, p. 27-38 12 p.

Research output: Contribution to journalArticle

401 Citations (Scopus)

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment

Dimopoulos, M. A., Stewart, A. K., Masszi, T., Spicka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A., San-Miguel, J., Ludwig, H., Ro, S., Aggarwal, S., Moreau, P. & Palumbo, A., 2017, In : Blood Cancer Journal. 7, 4, e554.

Research output: Contribution to journalArticle

27 Citations (Scopus)

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Avet-Loiseau, H., Fonseca, R., Siegel, D., Dimopoulos, M. A., Špička, I., Masszi, T., Hájek, R., Rosiñol, L., Goranova-Marinova, V., Mihaylov, G., Maisnar, V., Mateos, M. V., Wang, M., Niesvizky, R., Oriol, A., Jakubowiak, A., Minarik, J., Palumbo, A., Bensinger, W., Kukreti, V. & 4 others, Ben-Yehuda, D., Stewart, A. K., Obreja, M. & Moreau, P., Sep 1 2016, In : Blood. 128, 9, p. 1174-1180 7 p.

Research output: Contribution to journalArticle

65 Citations (Scopus)

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

Mesa, R., Verstovsek, S., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Zhen, H., Jones, M. M., Parasuraman, S., Li, J., Côté, I., Habr, D. & Vannucchi, A. M., Aug 1 2016, In : European journal of haematology. 97, 2, p. 192-200 9 p.

Research output: Contribution to journalArticle

27 Citations (Scopus)

Characterization and function of histamine receptors in human bone marrow stromal cells

Nemeth, K., Wilson, T., Rada, B., Parmelee, A., Mayer, B., Buzas, E., Falus, A., Key, S., Masszi, T., Karpati, S. & Mezey, E., Feb 1 2012, In : Stem Cells. 30, 2, p. 222-231 10 p.

Research output: Contribution to journalArticle

19 Citations (Scopus)
6 Citations (Scopus)

Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin

Skribek, H., Otvos, R., Flaberg, E., Nagy, N., Markasz, L., Eksborg, S., Masszi, T., Kozma, A., Adam, E., Miseta, A., Klein, E. & Szekely, L., Dec 1 2010, In : Experimental Hematology. 38, 12, p. 1219-1230 12 p.

Research output: Contribution to journalArticle

10 Citations (Scopus)

Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population

Mohl, A., Boda, Z., Jager, R., Losonczy, H., Marosi, A., Masszi, T., Nagy, E., Nemes, L., Obser, T., Oyen, F., Radványi, G., Schlammadinger, Á., Szélessy, Z. S., Várkonyi, A., Vezendy, K., Vilimi, B., Schneppenheim, R. & Bodó, I., May 1 2011, In : Journal of Thrombosis and Haemostasis. 9, 5, p. 945-952 8 p.

Research output: Contribution to journalArticle

10 Citations (Scopus)

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT

Giebel, S., Labopin, M., Potter, M., Poiré, X., Sengeloev, H., Socié, G., Huynh, A., Afanasyev, B. V., Schanz, U., Ringden, O., Kalhs, P., Beelen, D. W., Campos, A. M., Masszi, T., Canaani, J., Mohty, M. & Nagler, A., Jun 1 2018, In : European Journal of Cancer. 96, p. 73-81 9 p.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100

Krahling, T., Balassa, K., Kiss, K. P., Bors, A., Batai, A., Halm, G., Egyed, M., Fekete, S., Remenyi, P., Masszi, T., Tordai, A. & Andrikovics, H., Jan 2016, In : Cancer Epidemiology Biomarkers and Prevention. 25, 1, p. 98-104 7 p.

Research output: Contribution to journalArticle

15 Citations (Scopus)

Csontveló-transzplantációs program Magyarországon: beszámoló az 1990-1995 közötti idószakról.

Translated title of the contribution: The bone-marrow transplantation program in Hungary: report from the period 1990-1995Petrányi, G., Masszi, T., Tímár, L., Kriván, G., Pálóczi, K., Nagy, K., Fekete, S., Reményi, P., Torbágyi, E., Dénes, R. & Kelemen, E., Oct 6 1996, In : Orvosi hetilap. 137, 40, p. 2203-2208 6 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Daratumumab, bortezomib, and dexamethasone for multiple myeloma

Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., Mark, T. M., Qi, M., Schecter, J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Spencer, A. & Sonneveld, P., Aug 25 2016, In : New England Journal of Medicine. 375, 8, p. 754-766 13 p.

Research output: Contribution to journalArticle

572 Citations (Scopus)

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

Saglio, G., Hochhaus, A., Goh, Y. T., Masszi, T., Pasquini, R., Maloisel, F., Erben, P., Cortes, J., Paquette, R., Bradley-Garelik, M. B., Zhu, C. & Dombret, H., Aug 15 2010, In : Cancer. 116, 16, p. 3852-3861 10 p.

Research output: Contribution to journalArticle

88 Citations (Scopus)

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial

Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., Robak, T., Khoroshko, N., Masszi, T., Skotnicki, A., Hellmann, A., Zaritsky, A., Golenkov, A., Radich, J., Hughes, T., Countouriotis, A. & Shah, N., Jun 15 2007, In : Blood. 109, 12, p. 5143-5150 8 p.

Research output: Contribution to journalArticle

323 Citations (Scopus)

Diffusion weighted magnetic resonance imaging demonstrates tumor response following palliative embolization of a recurrent shoulder plasmacytoma

Bérczi, V., Rudas, G., Kozák, L. R. U., Györke, T., Mikala, G., Masszi, T., Kalina, I. & Kaposi, P. N., 2014, In : World Journal of Surgical Oncology. 12, p. 271 1 p.

Research output: Contribution to journalArticle

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

Andrikovics, H., Krahling, T., Balassa, K., Halm, G., Bors, A., Koszarska, M., Batai, A., Dolgos, J., Csomor, J., Egyed, M., Sipos, A., Remenyi, P., Tordai, A. & Masszi, T., Jul 1 2014, In : Haematologica. 99, 7, p. 1184-1190 7 p.

Research output: Contribution to journalArticle

62 Citations (Scopus)

Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning

Tordai, A., Bors, A., Kiss, K. P., Balassa, K., Andrikovics, H., Batai, A., Szilvasi, A., Rajczy, K., Inotai, D., Torbagyi, E., Lengyel, L., Barta, A., Remenyi, P. & Masszi, T., 2018, In : PloS one. 14, 6, e0218945.

Research output: Contribution to journalArticle

Open Access
3 Citations (Scopus)

Drugs, gene transfer, signaling factors: A bench to bedside approach to myocardial stem cell therapy

Vertesaljai, M., Piroth, Z., Fontos, G., Andreka, G., Font, G., Szantho, G., Lueff, S., Reti, M., Masszi, T., Ablonczy, L., Juhasz, E. D., Simor, T., Turner, M. S. & Andreka, P., Jun 1 2008, In : Heart Failure Reviews. 13, 2, p. 227-244 18 p.

Research output: Contribution to journalArticle

10 Citations (Scopus)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Ross, D. M., Masszi, T., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., Garcia-Gutierrez, V., Gattermann, N., le Coutre, P. D., Martino, B., Saussele, S., Giles, F. J., Radich, J. P., Saglio, G., Deng, W., Krunic, N., Bédoucha, V., Gopalakrishna, P. & Hochhaus, A., May 1 2018, In : Journal of cancer research and clinical oncology. 144, 5, p. 945-954 10 p.

Research output: Contribution to journalArticle

41 Citations (Scopus)

Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma: Single-center experience of 18 years

Remenyi, P., Varga, G., Mikala, G., Reti, M., Gopcsa, L., Batai, A., Csukly, Z., Lengyel, L., Torbagyi, E., Barta, A., Fabian, J., Levai, D., Szombath, G., Andrikovics, H. & Masszi, T., Jan 1 2016, In : Transplantation Proceedings. 48, 1, p. 177-184 8 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)

Effectiveness of intra-arterial steroid administration for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease

Bérczi, V., Tóth, A., Tatai, G., Fábián, J., Reményi, P. & Masszi, T., Jan 1 2019, (Accepted/In press) In : Clinical Radiology.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

Kiladjian, J. J., Guglielmelli, P., Griesshammer, M., Saydam, G., Masszi, T., Durrant, S., Passamonti, F., Jones, M., Zhen, H., Li, J., Gadbaw, B., Perez Ronco, J., Khan, M. & Verstovsek, S., Apr 1 2018, In : Annals of Hematology. 97, 4, p. 617-627 11 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)

Schneider, T., Rosta, A., Losonczy, H., Radványi, G., Ujj, G., Egyed, M., Illés, Á., Jakucs, J., Szerafin, L., Gasztonyi, Z., Masszi, T., Iványi, J., Demeter, J., Dombi, P., Tóth, A. & Borbényi, Z., Apr 1 2018, In : Pathology and Oncology Research. 24, 2, p. 199-205 7 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

European results of unrelated cord blood transplants

Gluckman, E., Rocha, V., Chastang, C., Abecasis, M., Arcese, W., Badell Serra, I., Beksac, M., Bernaudin, F., Bogdanic, V., Bosi, A., Cahn, J. Y., Cornu, G., Delliers, L. G., Dokal, I., Favre, C., Fernandez, M. N., Ferreira, E., Fisher, A., Gibson, B. E. S., Jedrzejcack, W. & 30 others, Jouet, J. P., Kinoshita, A., Kobylka, P., Laporte, J. P., Locatelli, F., Lutz, P., Masszi, T., Millone, J., Milovic, V., Miniero, R., Nagler, A., Ortega, J. J., Pasquini, R., Pension, A., Perez-Oyteza, J., Peters, C., Plouvier, E., Reiffers, J., Roberts, I., Roittman, S., Saarinen, U., Souillet, G., Stary, J., Takaue, Y., Urban, C., Veys, P., Vilmer, E., Vossen, J. M., Yaniv, I. & Zintl, F., Aug 13 1998, In : Bone Marrow Transplantation. 21, SUPPL. 3, p. S87-S91

Research output: Contribution to journalArticle

22 Citations (Scopus)

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis

Nicolini, F. E., Masszi, T., Shen, Z., Gallagher, N. J., Jootar, S., Powell, B. L., Dorlhiac-Llacer, P. E., Zheng, M., Szczudlo, T. & Turkina, A., May 1 2012, In : Leukemia and Lymphoma. 53, 5, p. 907-914 8 p.

Research output: Contribution to journalArticle

16 Citations (Scopus)